Consolidated Financial Result Briefing
for the three months ended June 30, 2025
CYBERDYNE Inc. (Ticker Code: 7779)
August 14, 2025
1Q FY2025 - Consolidated Results Summary (IFRS)
Consolidated revenue decreased due to factors such as the sale of a subsidiary in the previous fiscal year, while operating profit improved. Profit before tax and net profit turned positive, mainly due to gains on the valuation of investment securities.
Revenue
1,000 Million
YoY -156 Million (-13%)
・EMEA product rentals: +86 million yen (business +89 million yen, forex -2 million yen)
(Millions of yen) | 2024/1Q | 2025/1Q | YoY | % |
Revenue | 1,155 | 1,000 | -156 | -13% |
Operating profit (loss) | (154) | (100) | +54 | - |
Profit (loss) before tax | (7) | 433 | +440 | - |
Profit (loss) attributable to owners of parent | 11 | 251 | +240 | - |
・Domestic & APAC product rentals, etc.: +43 million yen (business +52 million yen, forex -9 million yen)
・Treatment services: -114 million yen (business -90 million yen, forex -23 million yen)
・New business expansion: LeyLine -139 million yen, domestic -32 million yen
Operating profit (loss)
-100 Million
YoY +54 Million
・EMEA product rentals: +75 million yen (business +78 million yen, forex -3 million yen)
・Domestic & APAC product rentals, etc.: +27 million yen (business +33 million yen, forex -6 million yen)
・Treatment services: -20 million yen (business -21 million yen, forex +1 million yen)
・New business expansion: LeyLine +22 million yen, domestic +10 million yen
・R&D and head office expenses, etc.: -61 million yen
・Operating profit variance: +54 million yen
Profit (loss) before tax 433 Million YoY +440 Million
・Gain on valuation of investment securities: +451 million yen (Q1 FY2025: +454 million yen vs. Q1 FY2024: +3 million yen)
・Financial income/expenses and others: -65 million yen
※ Exchange Rate USD/JPY: Mar 149.52 → Jun 144.81 (YoY: Mar 151.41 → Jun 161.07) EUR/JPY: Mar 162.08 → Jun 169.66 (YoY: Mar 163.24 → Jun 172.33)
Consolidated results: Revenue / Operating profit (Margin)
Product rentals and related services recorded year-on-year increases in both revenue and profit, with growth in EMEA (primarily Germany), APAC (primarily Malaysia), and Japan.
Treatment services experienced declines in both revenue and profit, partly due to a temporary impact from the change in the management structure of RHG in the U.S. at the beginning of the fiscal year. New business expansion recorded a decrease in revenue but an increase in profit, due to the sale of LeyLine at the end of the previous fiscal year.
(Millions of yen) | 2024/1Q | 2025/1Q | YoY | % | |
Product rental | Revenue Operating Profit (Margin %) | 408 170 (42%) | 537 272 (51%) | +129 +102 (+9pt) | +32% +60% |
Treatment service | Revenue Operating Profit (Margin %) | 523 -17 (-3%) | 409 -38 (-9%) | -114 -21 (-6pt) | -22% - |
New business | Revenue | 224 | 53 | -171 | -76% |
expansion | Operating Profit (Margin %) | -33 (-15%) | - 0 (-1%) | +32 (+14pt) | - |
R&D expenses & Head office expenses | Adjusted amount | -273 | -334 | -61 | - |
Consolidated total | Revenue | 1,155 | 1,000 | -156 | -13% |
(IFRS) | Operating Profit (Margin %) | -154 (-13%) | -100 (-10%) | +53 (+3pt) | - |
※1 Amount of profit or loss, which is revenue minus operating expenses, for each business
※2 Adjustment amount of R&D expenses, head office administrative expenses, other income and expenses, etc.
Product rental：Revenue from rental of the Group's products（includes revenue from sales)
Treatment service：Revenue from treatment services provided through the Group's facilities (including service fees in Robocare Centers)
New business expansion：Revenue from the Group's new business (e.g. subsidiary in Mobility and Sleeping App)
(Millions of yen) 2025/1Q (2024/1Q) | Japan | EMEA | APAC | AMER | Total | YoY |
Product rental | 246 (223) | 148 (61) | 135 (114) | 9 (10) | 537 (408) | +129 (+32%) |
Treatment Service | 32 (31) | 12 (9) | - | 365 (482) | 409 (523) | -114 (-22%) |
New business Expansion | 53 (85) | - (139) | - | - | 53 (224) | -171 (-76%) |
Total | 331 (340) | 159 (209) | 135 (114) | 374 (492) | 1,000 (1,155) | -156 (-13%) |
YoY | -9 (-3%) | -50 (-24%) | +20 (+18%) | -118 (-24%) | ||
Domestic | Foreign | |||||
Sales Revenue ratio | 33% | 67% | 100% | |||
Revenue from rental and sales (by product)
EMEA : Europe, the Middle East and Africa APAC : Asia-Pacific *Excluding Japan AMER：North, Central and South America
Revenue from rental and sales (by product)
Domestic sales increased mainly due to new installations of the Medical HAL Lower Limb Type.
Overseas sales increased mainly due to new installations in EMEA (primarily Germany) and APAC (primarily Malaysia).
(Millions of yen) 2025/1Q (2024/1Q) | Type of product | In Japan | Outside Japan | Total |
Medical HAL Lower Limb Type | 103 | 232 | 334 | |
Cybernics Treatment | (87) | (129) | (215) | |
Non-medical HAL Lower Limb Type | - | |||
Functional improvement and | 37 (42) | 37 (42) | ||
regeneration | ||||
HAL Single Joint Type | 24 | 35 | 58 | |
(22) | (26) | (48) | ||
Well-being and care | HAL Lumbar Type | 19 | 22 | 41 |
(25) | (21) | (46) | ||
HAL Lumbar Type | 8 | - | 8 | |
Labor Support | (9) | (9) | ||
Mobile robot (CL02 etc.) | - | |||
35 | 35 | |||
(13) | (13) | |||
Other（Acoustic X、Other products） | 19 | 3 | 23 | |
(25) | (10) | (35) | ||
Total | 245 (223) | 291 (186) | 537 (408) | |
Disclaimer
This presentation contains forward-looking statements concerning CYBERDYNE, Inc. and its Group's future plans, strategies and performance. Forward-looking statements contained in this presentation are based on information currently available and on certain assumption redeemed rational at the time of creation of this presentation. As such, due to various risks and uncertainties, the statements and assumption does not guarantee future performance, may be considered differently from alternative perspectives and may differ from the actual result.
Further, this presentation contains statements and information regarding corporate entities other than those belonging to the CYBERDYNE group, which have been complied from various publicly- available sources. CYBERDYNE does not verify nor guarantees accuracy and appropriateness of those information.